Tasocitinib: the new drug for healing cancer

AC220, PIK-93, Tivozanib, kinase inhibitor drugs, BI-2536 along with Tasocitinib are the latest inhibitors that have proved to be of great aid.

San Diego, CA (prHWY.com) March 4, 2011 - Tasocitinib targets a protein called JAK; hence, it is often referred to as a JAK inhibitor. The Pfizer study carried out on JAK trial is expected to bring about a path breaking results in this field. The cancer therapy which is directed towards correcting the problems of molecular alterations has often led to the growth in cancer cells. It has been a part of the treatment of advanced breast cancer and for gastrointestinal tumors. Unlike most novel, target-directed cancer drugs which come with pregenomic traits, this postgenomic natured drug is surely a smart drug capable of fundamentally changing the nature of the treatment of all cancers.

Apart from Tasocitinib, mention should be made about AC220 which is another inhibitor needed for the treatment of acute myeloid leukemia. It has proved to be potent, effective and has the ability to inhibit FLT3. Inhibitor PIK 93 works on the type III PI 4-kinase enzyme selectively.

The abstract Tivozanib is a quinoline urea derivative which is oral quinine in nature and composition. It acts as a potent and selective inhibitor against vascular endothelial growth factor also known as the VEGFR. According to the preclinical data tivozanib helps in combating the proliferation of endothelial cells in vitro by restricting its migration. It has the ability of suppressing angiogenesis and human tumor xenografts growth in vivo. Tivozanib has proved to be safe in nature and even orally bioavailable.

Hence, when applied on cancer patients, it proves to be effective yet safe. The inhibition of angiogenesis and suppression of tumor progression in several types of advanced cases of solid tumors has been possible through the application of the Tivozanib drug. But this drug is still under clinical investigation for the treatment of renal cell carcinoma and even for the non-small cell lung carcinoma. A combination of this compound can work well with chemotherapies in breast, gastrointestinal cancer patients etc. BI 2536 is another category of potent and selective inhibitor of Polo-like Kinase. It has the ability of inhibiting tumor growth in Vivo.

http://www.synkinase.com/

###

Tag Words: kinase inhibitor drugs, ac220, tivozanib

Categories: Health

Press Release Contact
Synkinase, PO Box 7890
San Diego CA, 92167, USA

1-877-854-6273

Link To This Press Release:

URL HTML Code